Biodesix (BDSX) Scheduled to Post Earnings on Friday

Biodesix (NASDAQ:BDSX) is scheduled to be releasing its earnings data before the market opens on Friday, November 1st. Analysts expect Biodesix to post earnings of ($0.08) per share for the quarter. Biodesix has set its FY 2024 guidance at EPS.Individual that wish to listen to the company’s earnings conference call can do so using this link.

Biodesix (NASDAQ:BDSX) last issued its earnings results on Wednesday, August 7th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. Biodesix had a negative return on equity of 505.95% and a negative net margin of 73.08%. The business had revenue of $17.93 million for the quarter, compared to analysts’ expectations of $16.05 million. During the same period in the previous year, the firm posted ($0.17) EPS. On average, analysts expect Biodesix to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Biodesix Stock Up 0.6 %

BDSX stock opened at $1.66 on Thursday. The company’s 50 day simple moving average is $1.73 and its 200-day simple moving average is $1.60. The company has a debt-to-equity ratio of 0.99, a current ratio of 3.28 and a quick ratio of 3.28. Biodesix has a 52-week low of $1.15 and a 52-week high of $2.21. The firm has a market capitalization of $240.99 million, a P/E ratio of -3.61 and a beta of 1.22.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Scotiabank started coverage on Biodesix in a research note on Monday, September 16th. They set a “sector outperform” rating and a $3.00 price target for the company. Craig Hallum assumed coverage on Biodesix in a research report on Friday, July 26th. They set a “buy” rating and a $3.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $3.06.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.